Villejuif

• A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly sympto … Ended recruitment
  2023-510453-41-00 5 2015-10-26 Castration resistant prostate cancer patients metastatic to bone.
• Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage … Ended recruitment
  2023-509136-25-00 5 2015-07-16 Stage III melanoma (AJCC R0) with histologically confirmed cutaneous m
• Phase III trial of laryngeal preservation comparating chemotherapy followed by radiotherapy to chemotherapy administrated during radiotherap … Ended recruitment
  2024-513976-16-00 5 2015-06-26 squamous cell carcinomas of the larynx or hypopharynx locally advance
• A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obi … Ended recruitment
  2023-509348-84-00 5 2015-04-27 Chronic Lymphocytic Leukemia
• An Efficacy and Safety Study of JNJ-42756493 in Participants with Urothelial Cancer Ended recruitment
  2023-510273-34-00 4 2015-04-24 Urothelial cancer
• A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas (REGOBONE) Ended recruitment
  2024-513455-33-00 4 2014-09-11 Bone sarcoma
• Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended recruitment
  2024-511096-15-00 5 2014-08-01 Breast Cancer
• A large-scale comparative study evaluating an intravenous treatment, cabazitaxel, and radiation therapy to the pelvic lymph nodes in patient … Ended recruitment
  2024-517622-25-00 5 2013-12-06 Patients with localized prostate cancer and high-risk features of rela
• Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy. Ended recruitment
  2024-511142-39-00 5 2013-09-06 BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer
• Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free … Ended recruitment
  2024-516198-61-00 5 2013-06-05 Patients with high risk of relapse, ER+ and HER2- primary non-metastat
• Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer acco … Ended recruitment
  2024-516996-34-00 5 2012-04-12 oestrogen-receptor (ER)-positive HER2-negative breast carcinoma
• Treatment protocol for osteosarcomas in children, adolescents and adults including a randomized trial and biological studies Ended recruitment
  2024-514756-32-00 5 2007-03-19 High grade osteosarcoma
• Phase 1b Study of Tarlatamab in Combination with YL201 with or without Anti-PD-L1 in Subjects with Extensive Stage Small Cell Lung Cancer (D … Halted
  2024-515903-21-00 3 2025-10-31 Extensive Stage Small Cell Lung Cancer (ES-SCLC)
• A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors Halted
  2024-512927-36-00 1 2025-10-30 Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
• IMMUNORARE5 : A national platform of 5 academic phase II trials coordinated by Lyon university hospital to assess the safety and the efficac … Halted
  2024-517254-99-00 4 2025-09-16 The patients enrolled in IMMUNORARE will be adult patients with 5 rar
• A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors Halted
  2024-516916-93-00 3 2025-09-08 This study will be a Phase 1b, global, multicenter, open-label, 2-part
• A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors with KRAS G12D Mutation Halted
  2023-507091-47-00 1 2025-02-10 Advanced or metastatic solid tumors
• Study of Taxane-Platinum followed by a maintenance with avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma … Halted
  2023-510559-41-00 4 2025-01-02 Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
• Use of electronic cigarettes for smoking cessation Halted
  2024-518135-10-00 5 2024-10-31 Smokers smoking at least 10 cigarettes/day in the past year
• A study to evaluate novel immunotherapy combinations in participants with advanced non-small cell lung cancer (NSCLC) Halted
  2023-508730-34-00 9 2024-07-10 Non-small cell lung cancer (NSCLC): - Locally advanced NSCLC where par
• A study of PF-08046050 (SGN-CEACAM5C) in adults with advanced solid tumors Halted
  2023-505858-18-00 1 2024-06-28 Pancreatic carcinoma
• A Trial to Study if REGN5837 in Combination with Odronextamab is Safe for Adult Participants with Aggressive B-cell Non-Hodgkin Lymphomas Halted
  2022-502137-26-00 1 2024-05-03 B-cell Non-Hodgkins Lymphoma (B-NHL)
• Spartalizumab and low-dose PAzopanib in Refractory or Relapsed solid TumOrs of pediatric and adults SPARTO Halted
  2024-513535-24-00 9 2022-05-02 Refractory or Recurrent Solid Tumor
• A Study of PF-08046031 in Adults With Advanced Melanoma and Other Solid Tumors Ended
  2024-514745-10-00 1 2025-06-23 Melanoma (or) malignant melanoma Non-small cell lung cancer Head and n

Showing 745–768 of 961 trials